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Abstract
Aristolochic acid nephropathy (AAN) is a global term including any form of toxic inter-
stitial nephropathy that is caused either by the ingestion of plants containing aristolochic 
acids (AA) as part of traditional phytotherapies or by the environmental contaminants 
in food. Originally, AAN was reported in Belgium in individuals having ingested slim-
ming pills containing powdered root extracts of a Chinese herb, Aristolochia fangchi. 
However, it is estimated that exposure to AA affects thousands of people all over 
the world, particularly in the Balkans, Taiwan and China. Despite warnings from the 
Regulatory Agencies regarding the safety of products containing AA, many AAN cases 
remain frequently described worldwide. This chapter aims at giving a global picture of 
AAN through the descriptions of clinical cases and animal models, which were devel-
oped to better understand the mode of action of AA when inducing acute/chronic kid-
ney diseases. Major advances in the translational research on biomarkers of AAN are 
reviewed, with an intended emphasis on the “omics” assessment of this nephrotoxicity.
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1. Introduction
The kidney plays a major role in the body homeostasis by regulating volume and composition 
of water fluids and by removing from blood waste products such as metabolites, drugs and 
xenobiotics. Due to these functions, the kidney is highly susceptible to toxic insults. During 
lifetime, the body is continuously exposed to numerous potentially toxic agents such as drugs 
© 2018 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
[1], chemicals and natural nephrotoxins [2]. Among these, herbal remedies and traditional 
phytotherapies constitute a major challenge. Indeed, traditional herbal remedies are consid-
ered harmless by the general population because they are from natural origin. Moreover, 
most patients using these natural products fail to inform their physicians of their use [2]. 
The following story demonstrates that the use of natural products, as all drugs, should be 
submitted to rigorous pharmacological and toxicological studies to determine their efficacy/
safety. Some natural products have displayed therapeutic effects [3], whereas some others 
have been found to be highly toxic for the human body [4]. Among them, the toxicity of 
aristolochic acids (AA) has been extensively studied during the last decades. The term aris-
tolochic acid nephropathy (AAN) includes any form of toxic interstitial nephropathy that is 
caused either by the ingestion of plants containing AA as part of traditional phytotherapies 
(formerly known as “Chinese herbs nephropathy”) or by the environmental contaminants 
in food (Balkan endemic nephropathy, see below) [5]. AA are compounds found in plants 
from the genus Aristolochia, belonging to the plant family Aristolochiaceae. In addition to its 
nephrotoxic effects, AA exposure has also been frequently associated with the development 
of urothelial malignancies [6] and was classified as a human carcinogen class I by the World 
Health Organization (WHO) and the International Agency for Research on Cancer (IARC) in 
2002 [7]. Since the identification of AAN in the early 1990s in Belgium [4], increasing cases 
of AA intoxications have been reported all over the world [8]. AAN incidence is particularly 
high in Asian countries because traditional medicines are very popular and the complexity of 
the pharmacopeia represents a high risk of AA intoxication due to some confusion between 
close species. In the Balkan areas, the chronic exposure to AA has been considered as the 
causative agent responsible for the so-called Balkan endemic nephropathy (BEN) that occurs 
following ingestion of food prepared with flour derived from contaminated grains [5, 9–14].
Despite warnings from the Food and Drug Administration (FDA), the European Medicines 
Agency (EMA) and IARC regarding the safety of products containing AA, AAN cases remain 
frequently described worldwide [5, 15, 16]. Moreover, given the fact that the nephrotoxic 
effect of AA is irreversible and that chronic kidney failure as well as carcinogenic effects 
may develop very slowly after the initial exposure, AAN and associated cancers are likely to 
become a major public health issue in the next few years [15, 16, 17].
This chapter aims at giving a global picture of AAN with an intended emphasis on the 
“omics” assessment of this nephrotoxicity, especially on the metabonomic investigation of 
urine samples. Indeed, it could represent a strategic tool allowing to identify early biomarkers 
following AA intoxication thereby providing an early detection of the toxicity and a rapid 
therapeutic intervention [18].
2. Clinical cases
Originally, AAN was reported in Belgium with more than 100 individuals having ingested 
slimming pills containing powdered root extracts of a Chinese herb, Aristolochia fangchi [4, 19]. 
A total of 75 patients have been treated in our Nephrology Department at Erasme Hospital. 
Among them, 50 out of 57 (F/M ratio 56/1) received a kidney transplant because of end-stage 
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renal disease (ESRD); 21 presented with urothelial carcinoma of the upper tract (invasive in 
two cases) or the bladder (three cystectomies required), leading to five deaths. Four additional 
kidney recipients developed cancer of the digestive tract, one developed a brain lymphoma 
and 8 lethal cardiovascular or infectious complications. Among the seven patients still fol-
lowed in 2018 for chronic kidney disease (CKD), a left nephroureterectomy had to be per-
formed for pelvic carcinoma. Only one case of metastatic urothelial carcinoma was diagnosed 
without concomitant CKD [6]. The causal link with the intake of pills containing AA was 
demonstrated by the detection of DNA adducts specific to AA metabolites in renal tissue 
samples (see Section 3).
Although, initially, the Belgian cohort only included over 100 patients, it is estimated that 
exposure to AA affects 100,000 people in the Balkans (where the total number of patients with 
kidney disease amounts to approximately 25,000), 8,000,000 people in Taiwan and more than 
100,000,000 in mainland China [20, 21]. In Asia, Aristolochia species is considered as an integral 
part of the herbology used in traditional Chinese medicine, Japanese Kampo and Ayurvedic 
medicine [8]. It is found within the same therapeutic family such as the Akebia, Asarum, 
Cocculus and Stephania plants. Referred by common names such as Mu Tong, Mokutsu and 
Fang Ji, they are used in a multitude of herbal mixtures for therapeutic use [22]. In the initial 
cohorts concerning iatrogenic nephropathy due to AA, most of the patients were described, 
exhibiting a rapid and progressive evolution toward CKD or ESRD [16]. A large series of 
patients described in China fixed the median rate of the degradation in glomerular filtration rate 
at ~3.5 ml/min/year [20]. The progression rate in environmental nephropathy due to AA is much 
slower, with the end-stage of renal failure occurring only after an evolution of 15–20 years [23].
3. Correlation between AA-DNA adducts, Aristolochic acid 
nephropathy and upper urinary tract carcinoma
Under normal physiological conditions, AA is bioactivated by the reduction of nitro com-
pounds into “aristolactams,” which tend to form covalent bonds with purine bases of 
DNA. The DNA adducts specific to aristolactams remain part of the body’s cell structure for 
several years after the patients’ initial exposure to AA. Consequently, their discovery in renal 
or cancerous tissues constitutes a biomarker, which may be related to a previous exposure to 
AA, which possibly occurred much earlier [24].
As mentioned earlier, 40–45% of end-stage AAN Belgian patients currently treated by dialysis 
or renal transplantation displayed multifocal high-grade transitional cell carcinomas, mainly in 
the upper urinary tract [6, 25]. As mentioned earlier, the detection of DNA adducts specific to 
AA metabolites (aristolactams) in nephroureterectomy pieces is still possible more than 10 years 
after exposure to AA [26]. The carcinogenic effect of AA can be explained by the fact that the 
DNA adducts formed in combination with aristolactams lead to a mutation of A: T →T: A in the 
tumor suppressor gene TP 53 [27]. This mutation has frequently been detected in the urothelial 
tumors of cases described in Taiwan and in the Balkans, whereas this mutation rarely occurs in 
tumors which are not related to the exposure to AA [28, 29]. This mutation is therefore consid-
ered as a complementary signature mutation for AA intoxication.
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Besides the high prevalence of upper tract urothelial carcinoma, it must be underlined that can-
cers of the bladder appeared in female Belgian patients who had undergone transplants more 
than 15 years after exposure to AA had been stopped [30]. Frequent iatrogenic exposure to 
AA in Taiwan explains why this region has the world’s highest level of urothelial cancers [31].
4. Experimental models of AA intoxication
In the 1980s, Mengs et al. had already pointed out AA toxicity and carcinogenicity in several 
experimental studies [32–34]. They developed diverse animal models using rats and mice of 
both sexes intoxicated with different doses of AA, during variable exposure times and using 
different routes of administration. They observed that oral or intravenous administration of 
high doses of AA was followed by death from acute renal failure within the next 15 days. 
The lethal dose 50 (LD
50
) ranged from 56 to 203 mg/kg orally and 38 to 83 mg/kg intrave-
nously, depending on species and gender [32]. Mengs reported that the kidneys were the 
most affected organs after intoxication confirming that they constitute AA main target [32].
Following the identification of AA as the agent responsible for AAN and BEN in 1993, vari-
ous animal models were developed to study underlying mechanisms of AA nephrotoxicity. 
To do so, Cosyns et al. established a model of female New Zealand White rabbits injected 
intraperitoneally (i.p.) with 0.1 mg/kg of a mixture of AA (AAI: 44%; AAII: 56%), 5 days a 
week during 17–21 months [35]. The same authors reported the development of renal fibrosis 
and urothelial tumors in rabbits as it occurred in patients, therefore supporting the causal role 
of AA in the pathology.
Our group also developed different models of AAN. In 2002, Debelle et al. showed that daily 
subcutaneous injection of 10 mg/kg of AA mixture (AAI: 40%; AAII: 60%) in salt-depleted 
rats induced interstitial fibrosis and renal failure within 35 days [36]. In 2005, Lebeau et al. 
analyzed the time course of structural and functional impairments of the proximal tubule in 
a rat model of AAN using the same protocol [37]. A biphasic evolution of renal dysfunction 
and morphological alterations was described. First, a phase of acute kidney injury (AKI) was 
characterized with structural abnormalities occurring within the first 3 days as attested by 
necrosis of proximal tubular epithelial cells (PTEC). Dysfunction of proximal tubule was also 
highlighted by an increase of biochemical parameters such as tubular proteinuria, N-acetyl-
β-D-glucosaminidase (NAG), α-glutathione S-transferase (α-GST), leucine aminopeptidase 
(LAP) and neutral endopeptidase (NEP) enzymuria. At day 35 of the protocol, a second phase 
was identified, mainly associated to morphological alterations along with the presence of 
severe tubular atrophy in an interstitial fibrotic environment. Moreover, tubular proteinuria, 
NAG, α-GST, LAP and NEP enzymuria were further enhanced at this timepoint character-
izing the later phase of chronic kidney injury.
Regarding mice models, it has been shown that mice from different strains displayed variable 
susceptibility to AA treatment. In this regard, Sato et al. published a study in which they 
compared three strains of inbred mice, BALB/c, C3H/He and C57BL/6 that received 2.5 mg/kg 
of AA (AAI: 55%; AAII: 45%) or AA sodium salt daily by i.p. injection or oral administration, 
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5 days a week for 2 weeks [38]. Characteristic tubulointerstitial lesions as well as parameters 
of renal dysfunction were observed in both strains intoxicated with AA. However, the suscep-
tibility to AA differed between the three strains tested. The authors postulated that these dif-
ferences might reflect diversity in AA metabolism and/or in the mechanisms of detoxification. 
Indeed, genetic polymorphisms have been identified as a major factor affecting the expres-
sion level and/or activity of enzymes involved in AA metabolism. The variations observed 
between the different strains could therefore be linked to such polymorphisms.
More recently, we also confirmed the biphasic evolution in a mouse model of AAN (Figure 1). 
C57Bl/6 J male mice were daily i.p. injected with a solution of AAI (3.5 mg/kg) for 4 days 
and then sacrificed at 5, 10 or 20 days after the first day of injection [15, 39]. The acute phase 
was identified at day 5 with necrosis of PTEC while at day 20, cystic tubules and tubuloint-
erstitial fibrosis was observed characterizing the features of a chronic phase. This transition 
from AKI to CKD has an important significance clinically. Indeed, it has been shown that 
patients surviving an episode of AKI present a significant risk of progression to CKD [40–42]. 
However, the mechanisms by which AKI might initiate the onset of CKD have not been fully 
described. Therefore, a better understanding of the pathological mechanisms of AAN along 
with the identification of early biomarkers could lead to therapeutic strategies to treat AKI or 
impede progression to CKD. Along these lines, animal models of AAN could be considered 
as a useful tool providing important insight on the underlying mechanisms of AKI-to-CKD 
transition. In this regard, we recently demonstrated that renal nitric oxide (NO) bioavailabil-
ity was significantly reduced during the AKI-to-CKD transition in our AAN model while 
L-Arginine supplementation appeared beneficial [39]. Indeed, L-Arg treatment restored renal 
NO bioavailability and reduced the severity of tubular necrosis, inflammation and fibrosis 
Figure 1. Renal histology of AA-induced tissue injury. A–D. Representative photomicrographs (×400 magnification) 
illustrating renal tissue injury with periodic acid-Schiff staining in Ctl (A), 5 days after AA intoxication (B), 10 days 
after AA intoxication (C) and 20 days after AA intoxication (D). Zones of necrotic proximal tubular epithelial cells are 
observed in AA intoxication at day 5, 10 and 20 after AA (B-D). Moreover, cystic tubules and proteinuria (*) are visible 
in mice treated with AA at day 10 and 20. E–H. representative photomicrographs (×400 magnification) illustrating 
collagen deposit with Sirius red staining in Ctl (E), 5 days after AA intoxication (F), 10 days after AA intoxication (G) and 
20 days after AA intoxication (H). Deposition of collagen I and III are observed in the interstitium of renal parenchyma 
in AA-treated mice at day 5 (D). Collagen deposition are even enhanced from day 10 to day 20 (G–H). Abbreviations: G, 
glomerulus; NT, necrotic tubule; CT: cystic tubules and PT, proximal tubule.
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AA-intoxicated mice. We concluded that reduced NO bioavailability contributes to the patho-
logical processes in AAN but also that L-Arg could represent a potential therapeutic tool to 
decrease the severity of acute-to-chronic transition.
5. Conventional biomarkers
In most AAN cases, renal failure was discovered by routine blood testing [43]. Typically, 
moderate hypertension developed with increased serum creatinine and severe anemia [8, 44]. 
Proteinuria from tubular origin was confirmed with elevated urinary excretion of five low 
molecular weight proteins (β2-microglobulin, cystatin C, Clara cell protein, retinal-binding 
protein and α1-microglobulin) [45]. Levels of urinary neutral endopeptidase (NEP), a 94 kDa 
ectoenzyme of the proximal tubule brush border, constitute a reliable indicator of the severity 
of renal disease. Indeed, it has been shown to reflect the proportion of brush borders remain-
ing intact at the apical side of proximal tubules. Urinary NEP was significantly decreased in 
patient with moderate renal failure and almost undetectable in those with ESRD, indicating 
the loss of the proximal tubule integrity [46]. A hallmark of the Belgian cohort of AAN cases is 
the rapid progression to an ESRD in nearly 70% of intoxicated patients [44]. The combination 
of rapidly progressive interstitial renal fibrosis with urothelial malignancy strongly suggests 
the diagnostic of AAN. Since 2015, a consensus regarding the definition of diagnostic criteria 
has been established [16]. AAN will be diagnosed in any individual who suffers from renal 
failure in combination with at least two of the following three criteria: (1) a renal histology 
highlighting interstitial fibrosis distributed along a corticomedullary gradient; (2) a history of 
herbal products consumption with the demonstration of the presence of AA and (3) the iden-
tification of AA-DNA adducts or the specific A:T → T:A transversion in the tumor suppressor 
gene TP 53 in a kidney tissue sample or in a urothelial tumor.
Until now, no serum or urinary biomarker has been identified for clinical utility in the diag-
nosis of AAN or BEN [16]. Although mechanistically informative, the conventional mark-
ers described in the previous paragraph display a lack of sensitivity. When abnormal levels 
of those markers are noticed, irreversible damages were already set up. In this regard, the 
‘omics’ approach could constitute a strategic tool to identify early markers which could allow 
an early therapeutic intervention [18].
6. Nephrotoxicity assessment by the ‘omics’ approach
The biomarkers conventionally used in toxicology are particularly useful to detect or to fol-
low the evolution of a very specific effect usually identified in advance. On the other hand, 
significant variations in the levels of such biomarkers are often too late since they only appear 
once severe or worse irreversible damages are already developed. Moreover, they are not 
appropriate to identify unknown or unexpected effects or to appreciate responses that result 
from several effects occurring simultaneously in various cell types, organs or systems.
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Toxicogenomics is a more recent discipline that broadly studies changes in genes (genomics), 
RNA (transcriptomics), proteins (proteomics) and metabolites (metabol(n)omics) in a whole 
living organism exposed to a xenobiotic substance causing subsequent adverse health effects 
[47]. The main goal in toxicogenomics is to obtain a global and integrated view of the molecu-
lar and cellular mechanisms underlying a toxic response. It is crucial to distinguish changes 
in basal expression, for example due to stress, from both adaptive and toxic responses. In 
addition, according to the principle of molecular homology, it is likely that substances sharing 
similar chemical structures will display close mode of toxic action by altering the same set 
of genes, proteins and metabolites. Therefore, reference databases can be built that contain 
characteristic expression profiles of reference toxicants [48]. The comparison of the expression 
profile induced by a tested molecule with the database allows a fine classification. From the 
properties of the identified class, the toxic behavior of the test substance can be predicted. 
Finally, thanks to the development of ‘high-throughput’ analytical techniques, the expression 
of thousands of genes at the level of RNA or proteins can be simultaneously measured in an 
organ/tissue subjected to the effect of a toxic substance. In parallel, changes in the metabolic 
composition of biofluids and biopsies can be assessed over time. These global measurements 
facilitate not only the observation of the effects of a molecule on the targeted tissues (on-
target), but also of the harmful effects on non-targeted tissues (off-target) [49].
In a recent review, conventional and toxicogenomics methods were compared to evaluate 
their potential to predict nephrotoxicity, genotoxicity and teratogenicity of traditional rem-
edies [50]. Toxicogenomics methods present the main advantage to allow a quick and simul-
taneous acquisition of multiple markers which can be next identified and related to cellular 
processes targeted by the tested compound. Focusing on the nephrotoxicity assessment, these 
new approaches could identify a set of proteins and metabolites which might be promising 
biomarkers indicative of very early cellular changes. Compared to conventional markers such 
as plasma creatinine and BUN, the “omics” indicators are more sensitive and more specific. 
On the protein side, Clusterin, Cystatin-C, and N-Gal/lipolcalin-2, among others, are now 
considered as excellent candidates to detect acute or chronic tubulotoxicity [51, 52] to such an 
extent that they have been accepted by regulatory agencies (FDA and EMA) for the detection 
of acute kidney injury in preclinical risk assessment. On the metabolite side, since the COMET 
(Consortium for Metabonomic Toxicology) project that evaluated the benefit of metabonom-
ics in the prediction of potential drug adverse effect [48], numerous nonclinical and clinical 
studies have reported the usefulness of urine metabolic markers to predict acute and chronic 
renal injuries. In rats, variations in plasma 3-methylhistidine (3-MH) and 3-indoxyl sulfate 
(3-IS) are now recognized as early predictors of a decline in glomerular filtration due to acute 
renal failure, while the combination of simultaneous changes in urine glucose, methylamines, 
hippurate and certain amino acids is associated with proximal tubule damages [53].
Of course, those new approaches in systems biology are far from being validated. Nevertheless, 
in association with in vivo models, they are already useful to mechanistically assess the 
nephrotoxicity of xenobiotics. Most importantly, many recent studies highlight their unique 
potential for translational research from benchside to bedside, especially for the diagnosis 
and follow up of AKI [54].
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Both genomic and transcriptomic approaches have already been applied to investigate the cel-
lular mechanisms of AA toxicity and tentatively reveal fingerprints of AA exposure. Human 
exome sequencing of urothelial carcinoma of the upper urinary tract from individuals chroni-
cally exposed to AA revealed characteristic and unusual somatic mutations predominantly 
located on the non-transcribed strand [55]. This AA-related mutational fingerprint was essen-
tially found in oncogenes and tumor suppressor genes. Using a molecular epidemiologic 
approach based on genome sequencing, the genome-wide mutational signature for AA was 
also detected in liver and kidney cancers in targeted Taiwanese and Chinese populations [56, 
57]. Exposure to AA in various animal species and in humans is detected by the presence 
of aristolactam-DNA adducts, with excellent results obtained on renal specimens by ultra-
performance liquid chromatography-electrospray ionization/multistage mass spectrometry 
(UPLC-ESI/MSn) [58]. Such DNA adducts represent the direct evidence of tissue exposure to 
AA, and according to these authors, they can serve as endpoints for cross-species extrapola-
tion of toxicity data and human risk assessment.
Proteomic analyses of urinary, plasma and renal tissue resulted in differential expression of 
several cytoskeletal, developmental and inflammatory kidney proteins, in both AA-exposed 
and control mice [59]. Using fluorogenic derivatization followed by high-performance liq-
uid chromatography analysis and liquid chromatography tandem mass spectrometry with 
a MASCOT database searching system, two altered proteins, thrombospondin type 1 and a 
G protein-coupled receptor, were identified as discriminating mice chronically exposed to 
AA [60]. A proteomic signature of AA-exposure was also identified in rat kidney: upregu-
lated proteins included ornithine aminotransferase, sorbitol dehydrogenase, actin, aspar-
toacylase, 3-hydroxyisobutyrate dehydrogenase and peroxiredoxin-1, while ATP synthase 
subunit β, glutamate dehydrogenase 1, regucalcin, glutamate-cysteine ligase regulatory 
subunit, dihydropteridine reductase, hydroxyacyl-coenzyme A dehydrogenase, voltage-
dependent anion-selective channel protein 1, prohibitin, and adenylate kinase isoenzyme 
4 were all downregulated [61]. Interestingly, some of those proteins presented obvious bio-
logical and medical significance.
From the metabol(n)omics side, several studies were conducted either in experimental ani-
mal models or in patients. For example, a GC-MS-based metabolomic study was performed 
to analyze urinary metabolites in AA-exposed rats over time [62]. Among all metabolic alter-
ations, eight metabolites were selected as potential metabolic biomarkers including meth-
ylsuccinic acid, nicotinamide, 3-hydroxyphenylacetic acid, citric acid, creatinine, uric acid, 
glycolic acid and gluconic acid. Four of them were considered as “early indicator” (methyl-
succinic acid, citric acid, creatinine and 3-hydroxyphenylacetic acid), while the others were 
defined as “late metabolic biomarker.” According to the authors, the metabolomics markers 
were more sensitive than conventional biomarkers of renal injury. Using a UPLC/QTOF-
HDMS analysis, a bench of lipids molecules including cholic and chenodeoxycholic acid 
were identified as excellent biomarkers to evaluate the progression from early to advanced 
AAN. Also, indoxyl sulfate, uric acid and creatinine were considered as good markers in 
severe cases of AAN. Interestingly, they were also reversible under treatments both in AAN 
rats and in CKD patients [63]. Using a 1H-NMR-based approach, we compared the urine 
metabonomic profiles of rats exposed to either AAI, AAII, or the mixture. Metabolic altera-
tions indicating a proximal tubule injury were observed in all treated groups. These dose-
dependent effects already noticed at early stages were morphologically confirmed at later 
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time points. Renal damages were more pronounced with the mixture or AAII alone than 
AAI alone [18].
1H NMR-based metabolomics was also applied to urine samples collected from BEN-diagnosed 
people treated by hemodialysis, in Romania and Bulgaria [64]. While samples from healthy 
volunteers from both countries coincided in the PCA scores plot, Bulgarian and Romanian 
BEN-suffering patients not only deviated from controls but also from each other. This study 
also suggested that metabonomic assessment could be predictive of impending morbidity 
before conventional criteria can diagnose BEN. Similar metabonomic approach was also 
applied to surplus of urine samples collected from Belgian women (acutely and mistakenly 
exposed to AA through diet pills) and Croatian patients (chronically exposed to AA through 
contaminated food) [65] (Figure 2). Interestingly, a clear discrimination of the Belgian patients 
from healthy volunteers was shown, and urine samples collected from individuals living in 
Croatian endemic regions as compared to Croatian inhabitants from non-endemic villages 
tended to separate from each other. Finally, both Belgian and Croatian patients displayed 
close urine metabolic profiles, suggesting a common etiology of both diseases.
In conclusion, the methods in toxicogenomics have already brought water to the mill of 
researches on nephropathies induced by AA. Thus, aristolactam-DNA adducts specific to the 
AA exposure were revealed by genomic methods. For their part, proteomic and metabolomic 
approaches have identified very early and specific biomarkers of tubular renal damage associ-
ated with exposure to AA. These same markers have also opened new mechanistic tracks on 
the toxic modes of action of AA at the molecular and cellular levels.
7. Conclusions
“AAN” is a global designation for any toxic interstitial nephropathy consecutive to the expo-
sure to aristolochic acids. Although the development of accurate experimental models and the 
validation of robust biomarkers these last decades have allowed a better mechanistic under-
standing of the mode of action of those natural substances, we are still facing many chal-
lenges. In particular, the need for early and more predictive indicators of AAN in both animal 
models and in clinics is urgent. Also, unveiling the role of altered renal hemodynamics in the 
pathogenesis as well as the molecular and cellular events leading from an acute to a chronic 
Figure 2. Scores plot comparing the 1HNMR spectra of urine samples from diseased Balkan women in red with the urine 
samples collected from healthy Belgian women, in black. PLS-DA model.
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kidney disease in patients is essential. To this respect, the omics technologies have already 
brought new pieces to the puzzle. Specifically, metabonomic applied to urine samples col-
lected from AA-exposed animals or AAN patients stands out as a very promising approach.
More philosophically, the history of AAN reminds us that natural products are not with-
out risk. The easy and uncontrolled access to such substances, for instance from suspicious 
sources on the Web, increases the risk of renewing this sad experience. A review of the most 
recent literature in the field of traditional medicines and remedies reinforces our belief that 
they should be subject to the same safety assessments as drugs, and that omic methods should 
be included at different steps of the assessment process.
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